Researchers at the University of Pennsylvania used AI to analyze over 400,000 Reddit posts from nearly 70,000 users discussing GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound. The analysis, published in Nature Health, surfaced patient-reported symptoms—particularly menstrual changes and temperature issues like chills and hot flashes—that appear underrepresented in clinical trials and regulatory data. The team stresses this doesn't prove the drugs cause these effects, but flags them as signals worth further study.
sciencedaily.com
· 2026-09-13
Researchers publishing in Nature on September 2 found that older female mice given a GLP-1 obesity drug lived longer than untreated mice and showed slower onset of several biological markers linked to aging. The finding builds on earlier mouse studies suggesting GLP-1 medications, typically used for obesity and type 2 diabetes, may have broader anti-aging effects beyond weight loss.
nature.com
· 2026-09-02
Researchers at UC Berkeley gave 20-month-old female mice daily low-dose subcutaneous semaglutide, the active ingredient in drugs like Ozempic and Wegovy, and compared them with saline-treated and calorie-restricted counterparts. Over months of treatment, the semaglutide group showed slowed markers of aging and, in a full lifespan cohort of about 80 mice, longer survival than untreated controls.
nature.com
· 2026-09-02
GoKawiil